Table 1.
Baseline demographic, comorbidity, and study characteristics of included studies.
| Author | Study design | Sample size | Intervention | LVEF inclusion criteria | Age, yr | Male, % | DM, % | BMI, kg/m2 | Follow up, yr |
|---|---|---|---|---|---|---|---|---|---|
| EMPEROR Preserved, 2020 | RCT | 2997/2991 | Empagliflozin | LVEF ≥ 40% | 71.8/71.9 | 55.4/55.3 | 48.9/49.2 | 29.7/29.9 | 2.18 |
| VERTIS CV, 2020 | RCT | 680/327 | Ertugliflozin | LVEF ≥ 45% | 63.8/64.7 | 65.6/63.3 | 100/100 | 32.6/32.9 | 3.5 |
| DECLARE-TIMI 58, 2019 | RCT | 399/409 | Dapagliflozin | LVEF ≥ 45% | NA | NA | 100/100 | NA | 4.2 |
| SCORED, 2021 | RCT | 1667 | Sotagliflozin | LVEF ≥ 50 | NA | NA | 1667 | NA | 1.3 |
| SOLOIST-WHF, 2021 | RCT | 127/129 | Sotagliflozin | LVEF ≥ 50 | NA | NA | 127/129 | NA | 0.8 |
| DELIVER Trial, 2022 | RCT | 3131/3132 | Dapagliflozin | LVEF ≥ 40% | 71.8/71.5 | 56.4/55.8 | 44.7/44.8 | NA | 2.3 |
DM = diabetes mellitus.